Stewart takes responsibility for maximising the value of Amarin’s lead product, AMR101, a new drug currently in Phase 3 clinical trials for the treatment of high triglycerides. The company has also completed enrolment to its Phase 3 Marine trial earlier than expected, with results now due early next year.
Stewart has more than 30 years of experience in the pharmaceutical industry, including five as ceo of CollaGenex Pharmaceuticals. He also worked for the ASTA Medica Group, where for 10 years he managed several business units in the US and internationally. He began his career in sales and marketing for Winthrop Laboratories, in the UK, and subsequently held a number of positions of increasing responsibility within the Sterling-Winthrop Group.
Declan Doogan, who has been the company’s interim ceo, will continue to support Amarin as chief medical officer for the majority of his time.
Amarin names Colin Stewart as president and ceo
Has been in the pharmaceutical industry for more than 30 years
You may also like
Packaging
How pharma packaging manufacturers role is evolving: the case of extractables testing
As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma